Preventing adverse drug-drug interactions: A need for improved data and logistics

Mayo Clinic Proceedings

Volumn 88, Issue 2, 2013, Pages 126-128

  Seminerio, Michael J ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXAMETHASONE; ERLOTINIB; ESOMEPRAZOLE; IMATINIB; KETOCONAZOLE; METHYLPREDNISOLONE; OMEPRAZOLE; PANTOPRAZOLE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; RITONAVIR; TERFENADINE;

ADVERSE DRUG REACTION; BIOAVAILABILITY; COMPUTER PROGRAM; DATA BASE; DRUG BLOOD LEVEL; DRUG INFORMATION; DRUG INTERACTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HUMAN; PHARMACY; PRESCRIPTION; UNITED STATES;

EID: 84876554499     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.12.005     Document Type: Editorial

References (19)

1. Bowlin J, Xia F, Wang W, Robinson K, Stanek E. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clinic Proc. 2013;88(2):139-148.
2. Beijen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489-496. (Pubitemid 39069399)
3. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546-548.
4. Bottiger Y, Sjoqvist F. Historical perspectives: drug interactionsdit all began with cheese. J Intern Med. 2010;268(6):512-515.
5. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. JAMA. 1993;269(12):1513-1518.
6. Duong S, Leung M. Should the concomitant use of erlotinib and acid-reducing agents be avoided? the drug interaction between erlotinib and acid reducing agents. J Oncol Pharm Pract. 2010;17(4):448-454.
7. Budha NR, Frymoyer A, Smelick, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pHdependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203-213.
8. US Food and Drug Administration. Erlotinib (Tarceva) Prescribing Information. Silver Spring, MD: US Food and Drug Administration; 2012.
9. Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Phamacol. 2010;70(6):908-911.
10. Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol. 2009;68(3):370-374.
11. van Erp EP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007;13(24):7394-7400.
12. Flippula AM, Laitila J, Neuvonen PJ, Backman JT. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012;165(8):2787-2798.
13. Filppula AM, Neuvonen M, Laitila J, et al. Autoinhibition of CYP3A4 leads to major role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013;41(1):50-59.
14. Haouala A, Widmer N, Duchosal MA, et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):75-87.
15. Saverno KR, Hines LE, Warholak TL, et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc. 2011; 18(1):32-37.
16. Yap KY, Raaj S, Chan A. OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. Int J Qual Health Care. 2010;22(2):93-106.
17. Grattagliano I, Portincasa P, D'Ambrosio G, et al. Avoiding drug interactions: here's help. J Fam Pract. 2010;59(6):322-329.
18. Ratain MJ. Personalized medicine: building the GPS to take us there. Clin Pharmacol Ther. 2007;81:321-322. (Pubitemid 46364492)
19. O'Donnell PH, Bush A, Spitz J, et al. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4): 446-449.